Company Overview of Agency for Science, Technology and Research
Agency for Science, Technology and Research operates as an agency for fostering scientific research and talent in Singapore. It nurtures public sector research and development in biomedical sciences, physical sciences, and engineering; and supports economic clusters by providing intellectual, human, and industrial capital to its partners in industry and healthcare sectors. The company supports, oversees, and coordinates public sector biomedical research and development activities; supports the development and growth of research scientists and engineers through secondment and attachment programs; manages the intellectual property created by research institutes and facilitates the transfer of ...
1 Fusionopolis Way
#20-10 Connexis North Tower
Founded in 2002
Key Executives for Agency for Science, Technology and Research
Managing Director and Executive Director
Chief Executive Officer of IE Singapore
Deputy Managing Director of Corporate & Legal and General Counsel
Chairman of Biomedical Research Council and Director
Executive Chairman of Exploit Technologies Pte Ltd
Compensation as of Fiscal Year 2013.
Agency for Science, Technology and Research Key Developments
Singapore's Agency for Science, Technology and Research and Cytos Biotechnology AG Announce it's Influenza Vaccine Demonstrates Favorable Immunogenicity and Tolerability
Jan 29 14
Singapore's Agency for Science, Technology and Research and Cytos Biotechnology AG announced that their influenza vaccine (gH1-Qbeta) met its primary end point for immunogenicity (seroconversion based on haemaglutination inhibition titres according to FDA criteria) in the phase 1 clinical trial in healthy Asian volunteers. The induced immune response showed good cross-reactivity to recent drifted H1N1 strains. The H1N1 influenza vaccine candidate is based on Cytos' proprietary bacteriophage Qbeta virus-like particle (VLP) technology. The clinical trial, commenced in May 2013 and completed enrollment and treatment of all 84 healthy volunteers in August 2013. During this trial the volunteers received two injections of the vaccine, 21 days apart. A*STAR and Cytos are announced that the vaccine was safe and well tolerated No serious adverse events were reported during the trial. The induced immune responses were comparable to that of approved seasonal influenza vaccines.
Nestle S.A. Signs Research Agreement with Agency for Science, Technology and Research
Jan 22 14
Nestle S.A. has entered into a strategic partnership with the Singapore government's Agency for Science, Technology and Research with the goal of setting up global research programmes in food science and technology. The agreement will focus on areas such as nutrition, packaging, data analytics and also biotransformation - the use of natural processes, such as fermentation, to transform raw materials into ingredients with nutritional or functional benefits. The agreement will allow Nestle to further expand its extensive expertise in areas of biotransformation including fermentation, enzyme technology and probiotics and to develop superior technology solutions to meet consumer expectations.
Agency for Science, Technology and Research and Debiopharm Group Teams Up to Develop New Cancer Drugs
Oct 11 13
Agency for Science, Technology and Research's and Debiopharm Group have signed an exclusive research collaboration to develop oral small molecules targeting new class of epigenetic modulators. Under the terms of the agreement, Debiopharm and ETC will co-finance the discovery phase of the project, whilst Debiopharm will be in charge of development.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|